Reporting positive and eagerly anticipated, potentially wider label-enabling data from a pair of phase IIb trials, Heron Therapeutics Inc.'s non-opioid HTX-011 took another leap forward on the road to marketing approval in postoperative pain, leaving farther behind any concerns regarding the recent add-on indication for Exparel (bupivacaine liposome injectable suspension) from Pacira Pharmaceuticals Inc.
Although Merck & Co. Inc. continues to chalk up investor-pleasing sales with Keytruda (pembrolizumab) and Bristol-Myers Squibb Co. (BMS) keeps doing well with Opdivo (nivolumab), researchers have yet to strike upon the best combinations with other agents.
At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Roche Holding AG reported disappointing news from the phase III Sandpiper study testing the phosphoinositide 3-kinase (PI3K) inhibitor taselisib in breast cancer, news that rocked the beleaguered drug class yet again. MEI Pharma Inc., however, is keeping faith with its PI3K prospect, which also yielded results at ASCO – and impressive ones.
Hopes for Flex Pharma Inc.'s phase II FLX-787 swirled down the drain – and so did the share price – after the company said clinical work is stopping because of oral tolerability concerns. Flex (NASDAQ:FLKS) ended Wednesday at $1.04, a loss of $3.14, or 75 percent.
Sage Therapeutics Inc. came a step closer in its bid to "rewrite the textbook on how depression should be treated," CEO Jeff Jonas told BioWorld, as the FDA rubber-stamped an expedited development route for type A gamma-aminobutyric acid (GABAA) modulator SAGE-217 in major depressive disorder (MDD). "We think this is a fundamental brain mechanism" with even wider applications, he said.
CHICAGO – Debates over the value of hyperthermic intra-peritoneal chemotherapy (HIPEC) may subside as cancer patients and their doctors learn of the French study done in patients undergoing surgery for colorectal peritoneal carcinomatosis. On the other hand, maybe they won't, because fans aplenty remain. "There are surgeons in the U.S. who are firm believers in HIPEC and others who are true skeptics," said Richard Schilsky, chief medical officer of the American Society of Clinical Oncology (ASCO). "If patients travel around, they're going to hear the entire spectrum" of opinion. In such a contentious environment, "to even be able to do a randomized study is quite remarkable," he said during ASCO's annual meeting. He also noted that the surgery is "technically demanding" and "takes its toll on both the surgeon and the patient."
Waltham, Mass.-based Deciphera Pharmaceuticals Inc.'s updated results from its phase I trial with DCC-2618, a broad-spectrum KIT and platelet-derived growth factor receptor (PDGFR) alpha inhibitor, in patients with gastrointestinal stromal tumors (GIST) at the American Society of Clinical Oncology (ASCO) meeting cheered investors.
